Editas Medicine Extends CRISPR Genome Editing Leadership Through Licensing of New CRISPR Technologies
December 19, 2016 07:00 ET
|
Editas Medicine
-- Company to Receive Global Licenses for Novel CRISPR System Cpf1 and Advanced Forms of Cas9 --CAMBRIDGE, Mass., Dec. 19, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading...